Ann: Appendix 3B, page-6

"They are marketing the stock to investors... not devices to clients... i.e. its about selling shares... raising capital through issuing more stock."

I agree entirely. You're assuming that this deal means that the capital raising is imminent. In contrast I believe that this indicates serious efforts are being made toward communicating the results to investors.

Once favourable results are out we will need to develop a production capacity. We already have a manufacturing partnership in place. Serious work is being done on the product design, which we hope includes optimisation for production, but there is no manufacturing line yet. That will take significant capital to establish. On favourable results we need to be ready to pounce upon the equity market with a clear and coherent business plan that clearly communicates the solid foundations of the device, the size and scope of the target market, the returns to be had from getting this product into that market, and the costs of achieving that. This is where we'll need an investor services partner. They know the equity market and understand the concerns of the investors.

"If future viability does rely on the binary outcome you have described itd make sense to raise before the outcome.... otherwise if results arent favourable all will be lost."

I think it pretty much is a binary outcome. The only way forward from negative results is if those results can be directly and strongly attributed to a flaw in the study, or a flaw in the physical design of the product that can be rectified. If the study represents a serious rebuttal of the underlying concepts of the treatment then all is almost certainly lost.


However... S3 Consortium are taking shares in payment. And at market price too; not even VWAP. That's a pretty strong endorsement from a company who could just as easily have insisted on cash in hand. They're clearly expecting binary 1.